4.6 Article

Role for Class I histone deacetylases in multidrug resistance

Journal

EXPERIMENTAL CELL RESEARCH
Volume 318, Issue 3, Pages 177-186

Publisher

ELSEVIER INC
DOI: 10.1016/j.yexcr.2011.11.010

Keywords

Histone deacetylases; Multidrug resistance; P-gp; Sp1

Funding

  1. Longyi Team
  2. National Base of TCM Clinical Research [LYTD-05]
  3. 111 Project [B07023]
  4. National Nature Science Foundation of China [81173224]

Ask authors/readers for more resources

Recent reports have showed that histone deacetylase (HDAC) inhibitor resulted in multidrug resistance (MDR) to other chemotherapeutic agents. However, the molecular mechanisms of Class I HDACs on MDR regulation are poorly understood. In this study, HDAC1 and HDAC2 acted as enhancers to intensify the chemosensitivities of anti-cancer drugs via reducing the expression levels of P-gp, MRP1 and MRP2. Furthermore, the dissociation of HDAC1 and HDAC2 led to transcriptional regulation of P-gp expression via the recruitment of p300, PCAF and NF-Y to the P-gp promoter region, which subsequently increased the level of the active gene marker, hyperacetylated histone H3. In parallel, selective inhibition of HDAC1 and HDAC2 induced the recruitment of p300, PCAF, NF-Y via acetylation of Sp1. Thus, our findings showed HDAC1 and 2 regulated P-gp expression through dynamic changes in chromatin structure and transcription factor association within the promoter region. Crown Copyright (C) 2011 Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available